The global subcutaneous biologics market is on a strong growth trajectory, projected to expand from USD 1.89 billion in 2024 to USD 5.37 billion by 2034, marking a robust CAGR of 11.09%. This surge is largely driven by the increasing demand for self-administered therapies, patient-friendly delivery methods, and advancements in biologics and drug delivery technologies.
Biologics are complex therapies derived from living cells, including monoclonal antibodies, vaccines, gene therapies, and more. These are administered either intravenously (IV) or subcutaneously (SC). Subcutaneous administration involves injecting the drug directly into the fatty tissue beneath the skin, allowing for slower and sustained absorption, making it a preferred route for many therapies.
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/download-databook/5726
2024 Market Size: USD 1.89 Billion
2034 Forecast: USD 5.37 Billion
Growth Rate (2025–2034): 11.09% CAGR
Regional Leader: North America
Fastest-Growing Region: Asia-Pacific
Dominant in 2024: Antibodies led the market revenue.
Emerging Leader: Nucleotides are anticipated to witness rapid growth.
Top Contributor in 2024: Injections
Fast-Growing Segment: Infusion methods are gaining traction due to ease of use and patient compliance.
Leading Segment: Autoimmune disorders
Highest Projected Growth: Oncological disorders due to increasing cancer cases and advancements in immunotherapy.
Get All the Details in Our Solutions – Access Report Preview: https://www.towardshealthcare.com/download-sample/5726
Subcutaneous delivery is revolutionizing patient care by enabling home-based treatment. It eliminates the need for clinical visits, improves treatment adherence, and promotes a more patient-centric approach.
Novartis & Lindy Biosciences (Aug 2024): Partnered to develop single-dose injectables using microglassification technology.
OneSource & Bhami’s Research Laboratory (Aug 2024): Collaborated on HILOPROO technology to reduce viscosity for high-concentration biologics.
Artificial Intelligence (AI) is increasingly being embedded into smart drug delivery systems. AI can:
Automate dose measurement and reminders
Ensure regulatory compliance
Provide real-time insights to healthcare professionals
Enhance personalized dosing and medication adherence
If you have any questions, please feel free to contact us at sales@towardshealthcare.com
Dominated the global market in 2024, backed by cutting-edge healthcare infrastructure and the presence of key players.
Poised to grow at the fastest rate, driven by:
Booming biotech industry
Government support
Rising chronic disease prevalence
India leads with the highest number of biosimilar approvals (95), while China’s NMPA approved 93 biologics in 2024 alone.
Expected to show significant growth due to:
Strategic investments in R&D
Government-funded life sciences initiatives
Germany and the UK are spearheading the push with billion-dollar funding for biologics manufacturing.
May 2025: Biocon and Yoshindo launched Ustekinumab BS for psoriasis and arthritis in Japan.
Jan 2025: FDA approved LEQEMBI, a subcutaneous autoinjector for Alzheimer’s, by Eisai and Biogen.
Dr. Enriqueta Felip endorsed Merck’s SC pembrolizumab, citing reduced burden on patients and clinicians with consistent efficacy.
The subcutaneous biologics market is steering toward a future of accessible, convenient, and effective therapy delivery. With innovations in biologics formulation, smart injectors, and supportive government policies worldwide, the sector is on a path of exponential growth.
As self-care and precision medicine become mainstream, subcutaneous biologics are not just an alternative—they’re fast becoming the preferred choice for both patients and providers.
Source : https://www.towardshealthcare.com/insights/subcutaneous-biologics-market-sizing
Kedrion Biopharma has announced that its human coagulation factor X concentrate, COAGADEX®, has been granted orphan drug designation by the… Read More
enecard PBF, a pioneer in pharmacy benefit facilitation, has announced a strategic partnership with DecisionRX, Inc., a leader in medication… Read More
In a high-stakes biotech industry where drug development can span over a decade, four small but determined biotech companies are… Read More
cell-free DNA and precision medicine, has officially announced the launch of the TEODOR trial (ABCSG 61), a groundbreaking phase 2,… Read More
The global interventional radiology market is witnessing rapid expansion, driven by advancements in minimally invasive procedures, rising demand for diagnostic… Read More
The global physical therapy market is valued at USD 28.06 billion in 2024, growing to USD 29.18 billion in 2025… Read More